Clinical trial for Atrial Fibrillation (AF)
Official title Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
ClinicalTrials.gov ID: NCT07272902
What this study is testing
What is Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)?
investigational drug regimen being studied as a potential treatment for atrial fibrillation in people with heart failure is designed to slow the heart rate and improve heart rhythm by blocking beta‑adrenergic receptors, inhibiting calcium channels, or increasing vagal tone
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if a larger trial can be done and which treatment, ablation or medicines, better supports survival, reduces hospital stays, and improves quality of life.
- Who it's for
- Adults who have atrial fibrillation and heart failure with preserved or mildly reduced ejection fraction.
- What's involved
- Participants will be randomly assigned to either a catheter ablation (a quick procedure that destroys tissue causing irregular beats) or medicines that control heart rate, with follow‑up visits and tests to monitor outcomes.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years
- Diagnosis of atrial fibrillation (documented on Holter, rhythm strip, or ECG)
- New York Heart Association (NYHA) class II-III heart failure
- Left ventricular ejection fraction (LVEF) \>40%
- If HF hospitalization within 6 months prior to screening: NT-proBNP \>200 pg/ml (if not in AF at screening) or \>600 pg/ml (if in AF at screening)
You likely can't join if
- Permanent atrial fibrillation diagnosis
- Prior catheter ablation for atrial fibrillation
- NYHA class IV heart failure
- Rheumatic heart disease
- Moderate or severe mitral stenosis
- Mechanical mitral valve
See the full eligibility criteria
- Age ≥18 years
- Diagnosis of atrial fibrillation (documented on Holter, rhythm strip, or ECG)
- New York Heart Association (NYHA) class II-III heart failure
- Left ventricular ejection fraction (LVEF) \>40%
- If HF hospitalization within 6 months prior to screening: NT-proBNP \>200 pg/ml (if not in AF at screening) or \>600 pg/ml (if in AF at screening)
- Otherwise: NT-proBNP \>300 pg/ml (if not in AF at screening) or \>900 pg/ml (if in AF at screening)
- On stable guideline-directed medical therapy for ≥1 month
- On stable diuretic dose for ≥2 weeks
- Suitable for either ablation-based rhythm control or rate control strategy
- Permanent atrial fibrillation diagnosis
- Prior catheter ablation for atrial fibrillation
- NYHA class IV heart failure
- Rheumatic heart disease
- Moderate or severe mitral stenosis
- Mechanical mitral valve
- Severe aortic stenosis or severe aortic/mitral regurgitation
- Renal failure requiring dialysis
- Contraindication to oral anticoagulation
- Infiltrative cardiomyopathies
- Complex congenital heart disease
- Untreated thyroid disease
- Acute coronary syndrome or coronary artery bypass surgery within 12 weeks
- Participation in another clinical trial
- Inability to provide informed consent
- Other serious non-cardiovascular condition with life expectancy ≤1 year
- Age \<18 years
The study team makes the final eligibility decision.
Where it is enrolling
- Halifax, Nova Scotia, Canada
- Hamilton, Ontario, Canada
- London, Ontario, Canada
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Halifax, Nova Scotia, Canada; Hamilton, Ontario, Canada; London, Ontario, Canada; Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.